GSA Capital Partners’s Ocular Therapeutix OCUL Stock Holding History

GSA Capital Partners’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$262K	Buy	+26,707	New	+$242K	0.02%	1381
2026 Q1	–	Sell	-35,098	Closed	-$426K	–	2041
2025 Q4	$426K	Sell	35,098 -80,455	-70%	-$977K	0.04%	927
2025 Q3	$1.35M	Buy	+115,553	New	+$1.38M	0.11%	228
2025 Q2	–	Sell	-15,306	Closed	-$112K	–	2031
2025 Q1	$112K	Buy	+15,306	New	+$118K	0.01%	1485
2024 Q4	–	Sell	-126,681	Closed	-$1.1M	–	1903
2024 Q3	$1.1M	Buy	+126,681	New	+$1.04M	0.08%	417
2024 Q2	–	Sell	-28,741	Closed	-$262K	–	1921
2024 Q1	$262K	Sell	28,741 -218,162	-88%	-$1.55M	0.02%	1291
2023 Q4	$1.1M	Buy	246,903 +13,321	+6%	+$39.4K	0.09%	343
2023 Q3	$733K	Buy	233,582 +114,629	+96%	+$469K	0.06%	567
2023 Q2	$614K	Buy	+118,953	New	+$707K	0.06%	616
2022 Q3	–	Sell	-127,978	Closed	-$514K	–	1774
2022 Q2	$514K	Buy	127,978 +70,358	+122%	+$266K	0.08%	485
2022 Q1	$285K	Buy	+57,620	New	+$319K	0.04%	928
2019 Q4	–	Sell	-11,222	Closed	-$34K	–	1639
2019 Q3	$34K	Buy	+11,222	New	+$50.2K	﹤0.01%	1335
2018 Q2	–	Sell	-15,600	Closed	-$102K	–	1858
2018 Q1	$102K	Buy	+15,600	New	+$87.8K	0.01%	1528
2015 Q3	–	Sell	-12,412	Closed	-$261K	–	1946
2015 Q2	$261K	Buy	+12,412	New	+$308K	0.01%	1682

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSA Capital Partners's OCUL Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 26,707 shares worth $262K. The stake represents 0.02% of the portfolio and ranks #1381 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in OCUL as recently as Q4 2025.

GSA Capital Partners first reported a position in OCUL in Q2 2015 and has held it in 14 quarters since. The position peaked at $1.35M in Q3 2025. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

GSA Capital Partners held 26,707 shares of Ocular Therapeutix worth $262K as of Q2 2026.
Ocular Therapeutix was a new GSA Capital Partners position in Q2 2026.
Ocular Therapeutix made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1381 holding.
GSA Capital Partners first reported a position in Ocular Therapeutix in Q2 2015 and has held it in 14 quarters since.
GSA Capital Partners's Ocular Therapeutix position peaked at $1.35M in Q3 2025.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.